For the quarter ending 2026-03-31, TNONW had $3,944K increase in cash & cash equivalents over the period. $5,586K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 6,248 | -3,339 | -6,385 |
| Stock-based compensation expense | -1,016 | 58 | 1,289 |
| Depreciation and amortization | -79 | 77 | 90 |
| Amortization of debt discount | 176 | - | - |
| Change in fair value of derivative liabilities | 45 | - | - |
| Amortization of operating right-of-use asset | -134 | 68 | 131 |
| Provision for credit losses on accounts receivable | 11 | 0 | 0 |
| Accounts receivable | -166 | 541 | -93 |
| Inventory | -802 | 484 | 70 |
| Prepaid expenses and other assets | -225 | -171 | 374 |
| Accounts payable | -465 | -259 | 525 |
| Accrued expenses | -563 | 499 | 142 |
| Operating lease liability | 145 | -74 | -138 |
| Net cash used in operating activities | 5,561 | -3,824 | -4,697 |
| Purchase of assets from sivantage, inc | - | -750 | - |
| Purchases of property and equipment | -25 | -111 | 192 |
| Cash used in investing activities | 775 | -639 | -192 |
| Gross proceeds from issuance of common stock, prefunded warrants and warrants | - | - | 4,010 |
| Gross proceeds from issuance of series a convertible preferred stock | - | 0 | 0 |
| Gross proceeds from issuance of series b convertible preferred stock | - | 0 | - |
| Gross proceeds from issuance of common stock, prefunded warrants and warrants | - | 4,010 | - |
| Gross proceeds from issuance of common stock | - | 0 | 0 |
| Gross proceeds from issuance of common stock, prefunded warrants and warrants under inducement agreement | - | 0 | 3,057 |
| Gross proceeds from issuance of convertible notes | 4,300 | - | - |
| Gross proceeds from issuance of common stock upon exercise of warrants | - | 0 | - |
| Offering costs | -375 | -59 | 867 |
| Net cash provided by financing activities | -2,392 | 59 | 6,200 |
| Effect of foreign currency translation on cash flow | - | 0 | 0 |
| Net increase in cash and cash equivalents | 3,944 | -4,404 | 1,311 |
| Cash and cash equivalents at beginning of period | 3,442 | 6,535 | - |
| Cash and cash equivalents at end of period | 4,607 | 3,442 | - |
Tenon Medical, Inc. (TNONW)
Tenon Medical, Inc. (TNONW)